Encapsulated Glioma — Trials

Encapsulated Glioma — Trials · CancerIndex

Clinical trials

Registered studies

328 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 116
Recruiting: 55
Ph III recruiting: 5
Growth YoY: —
Industry share: 15%
Top sponsor: National Cancer Institute (NCI)
Termination share: 40.8%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (51)

clinicaltrialsPublishedShowing 51–53 of 53 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06521567	A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer	active not recruiting	Phase 1 / Phase 2	83	GlaxoSmithKlineINDUSTRY	6	Nov 12, 2025	clinicaltrials
NCT04164901	Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)	active not recruiting	Phase 3	331	Institut de Recherches Internationales ServierOTHER	11	Apr 3, 2025